Table 1.
Comparison of clinical measurements in the patients with RA treated with bisphosphonates and denosumab at enrollment
| Variable | Bisphosphonate group (n = 50) | Denosumab group (n = 56) | p value |
|---|---|---|---|
| Age (years) | 67.6 (7.4) | 71.1 (8.2) | 0.035* |
| Height (cm) | 152.2 (6.4) | 151.4 (5.7) | 0.57 |
| Body weight (kg) | 54.3 (10.8) | 52.3 (10.1) | 0.32 |
| BMI | 23.4 (4.4) | 22.8 (3.9) | 0.73 |
| Disease duration (years) | 9.7 (5.1) | 11.3 (5.2) | 0.12 |
| bDMARDs use, n (%) | 30 (60) | 25 (44.6) | 0.12 |
| Etanercept (50 mg), n (%) | 2 (4) | 3 (5.4) | 0.74 |
| Golimumab (50 mg), n (%) | 4 (8) | 3 (5.4) | 0.58 |
| Tocilizumab (162 mg), n (%) | 8 (16) | 7 (12.5) | 0.6 |
| Sarilumab (200mg), n (%) | 4 (8) | 4 (7.1) | 0.86 |
| Abatacept (125mg), n (%) | 12 (24) | 8 (14.3) | 0.2 |
| MTX use, n (%) | 38 (76) | 26 (46.4) | 0.02* |
| MTX dose, mg/week | 7.3 (1.8) | 6.5 (2.1) | 0.11 |
| Prednisone use n (%) | 22 (44) | 18 (32.1) | 0.21 |
| Prednisone dose, mg/day | 5.36 (1.4) | 5.4 (2.3) | 0.72 |
| Modified sharp erosion score (0–280) | 36.1 (43.1) | 29.6 (33.9) | 0.63 |
| Modified Sharp JSN score (0-168) | 24.1 (36.5) | 23.1 (29.3) | 0.21 |
| Modified total sharp score (0–448) | 60.1 (79.3) | 52.5 (62.5) | 0.98 |
| DAS28-CRP | 3.1 (1.1) | 2.83 (1.2) | 0.28 |
| VAS | 28.8 (17.7) | 29.2 (19.7) | 0.82 |
| mHAQ | 0.52 (0.43) | 0.64 (0.77) | 0.87 |
| ACPA titer (U/ml) | 109.7 (171.3) | 141.1 (246.9) | 0.56 |
| MMP3 (ng/ml) | 94.3 (48.3) | 104.9 (69.9) | 0.74 |
| BMD | |||
| Lumbar spine (g/cm2) | 0.89 (0.17) | 0.86 (0.16) | 0.29 |
| Femoral neck (g/cm2) | 0.58 (0.11) | 0.56 (0.11) | 0.52 |
| Total hip (g/cm2) | 0.69 (0.13) | 0.67 (0.14) | 0.44 |
| Vertebral fracture, n (%) | 10 (20) | 14 (25) | 0.45 |
Results are expressed as the mean and standard deviation
BMI body mass index, DMARDs disease-modifying antirheumatic drugs, MTX methotrexate, DAS disease activity score, CRP C-reactive protein, VAS visual analogue scale, HAQ Health Assessment Questionnaire, ACPA anti-cyclic citrullinated peptide antibody, MMP3 matrix metalloproteinase, BMD bone mineral density
*p < 0.05 by Mann–Whitney U test